Statement: At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder.
Primary_evidence: Adverse Events 1:   Total: 81/353 (22.95%)   Febrile neutropenia * 13/353 (3.68%)   Anaemia * 21/353 (0.28%)   Neutropenia * 25/353 (1.42%)   Thrombocytopenia * 20/353 (0.00%)   Hypercoagulation * 21/353 (0.28%)   Leukopenia * 21/353 (0.28%)   Atrial fibrillation * 1/353 (0.28%)   Cardiac failure * 0/353 (0.00%)   Cardiac failure congestive * 0/353 (0.00%)   Myocardial infarction * 1/353 (0.28%) Adverse Events 2:   Total: 86/361 (23.82%)   Febrile neutropenia * 0/361 (0.00%)   Anaemia * 25/361 (1.39%)   Neutropenia * 20/361 (0.00%)   Thrombocytopenia * 22/361 (0.55%)   Hypercoagulation * 20/361 (0.00%)   Leukopenia * 20/361 (0.00%)   Atrial fibrillation * 0/361 (0.00%)   Cardiac failure * 0/361 (0.00%)   Cardiac failure congestive * 0/361 (0.00%)   Myocardial infarction * 0/361 (0.00%)